Cargando…
Towards a population-based threshold of protection for COVID-19 vaccines
Correlates of protection for COVID-19 vaccines are urgently needed to license additional vaccines. We measured immune responses to four COVID-19 vaccines of proven efficacy using a single serological platform. IgG anti-Spike antibodies were highly correlated with ID50 neutralization in a validated p...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673730/ https://www.ncbi.nlm.nih.gov/pubmed/34933765 http://dx.doi.org/10.1016/j.vaccine.2021.12.006 |
_version_ | 1784615511378624512 |
---|---|
author | Goldblatt, David Fiore-Gartland, Andrew Johnson, Marina Hunt, Adam Bengt, Christopher Zavadska, Dace Snipe, Hilda Darta Brown, Jeremy S. Workman, Lesley Zar, Heather J. Montefiori, David Shen, Xiaoying Dull, Peter Plotkin, Stanley Siber, George Ambrosino, Donna |
author_facet | Goldblatt, David Fiore-Gartland, Andrew Johnson, Marina Hunt, Adam Bengt, Christopher Zavadska, Dace Snipe, Hilda Darta Brown, Jeremy S. Workman, Lesley Zar, Heather J. Montefiori, David Shen, Xiaoying Dull, Peter Plotkin, Stanley Siber, George Ambrosino, Donna |
author_sort | Goldblatt, David |
collection | PubMed |
description | Correlates of protection for COVID-19 vaccines are urgently needed to license additional vaccines. We measured immune responses to four COVID-19 vaccines of proven efficacy using a single serological platform. IgG anti-Spike antibodies were highly correlated with ID50 neutralization in a validated pseudoviral assay and correlated significantly with efficacies for protection against infection with wild-type, alpha and delta variant SARS-CoV-2 virus. The protective threshold for each vaccine was calculated for IgG anti-Spike antibody. The mean protective threshold for all vaccine studies for WT virus was 154 BAU/ml (95 %CI 42–559), and for studies with antibody distributions that enabled precise estimation of thresholds (i.e. leaving out 2-dose mRNA regimens) was 60 BAU/ml (95 %CI 35–102). We propose that the proportion of individuals with responses above the appropriate protective threshold together with the geometric mean concentration can be used in comparative non-inferiority studies with licensed vaccines to ensure that new vaccines will be efficacious. |
format | Online Article Text |
id | pubmed-8673730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86737302021-12-16 Towards a population-based threshold of protection for COVID-19 vaccines Goldblatt, David Fiore-Gartland, Andrew Johnson, Marina Hunt, Adam Bengt, Christopher Zavadska, Dace Snipe, Hilda Darta Brown, Jeremy S. Workman, Lesley Zar, Heather J. Montefiori, David Shen, Xiaoying Dull, Peter Plotkin, Stanley Siber, George Ambrosino, Donna Vaccine Article Correlates of protection for COVID-19 vaccines are urgently needed to license additional vaccines. We measured immune responses to four COVID-19 vaccines of proven efficacy using a single serological platform. IgG anti-Spike antibodies were highly correlated with ID50 neutralization in a validated pseudoviral assay and correlated significantly with efficacies for protection against infection with wild-type, alpha and delta variant SARS-CoV-2 virus. The protective threshold for each vaccine was calculated for IgG anti-Spike antibody. The mean protective threshold for all vaccine studies for WT virus was 154 BAU/ml (95 %CI 42–559), and for studies with antibody distributions that enabled precise estimation of thresholds (i.e. leaving out 2-dose mRNA regimens) was 60 BAU/ml (95 %CI 35–102). We propose that the proportion of individuals with responses above the appropriate protective threshold together with the geometric mean concentration can be used in comparative non-inferiority studies with licensed vaccines to ensure that new vaccines will be efficacious. The Author(s). Published by Elsevier Ltd. 2022-01-21 2021-12-15 /pmc/articles/PMC8673730/ /pubmed/34933765 http://dx.doi.org/10.1016/j.vaccine.2021.12.006 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Goldblatt, David Fiore-Gartland, Andrew Johnson, Marina Hunt, Adam Bengt, Christopher Zavadska, Dace Snipe, Hilda Darta Brown, Jeremy S. Workman, Lesley Zar, Heather J. Montefiori, David Shen, Xiaoying Dull, Peter Plotkin, Stanley Siber, George Ambrosino, Donna Towards a population-based threshold of protection for COVID-19 vaccines |
title | Towards a population-based threshold of protection for COVID-19 vaccines |
title_full | Towards a population-based threshold of protection for COVID-19 vaccines |
title_fullStr | Towards a population-based threshold of protection for COVID-19 vaccines |
title_full_unstemmed | Towards a population-based threshold of protection for COVID-19 vaccines |
title_short | Towards a population-based threshold of protection for COVID-19 vaccines |
title_sort | towards a population-based threshold of protection for covid-19 vaccines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673730/ https://www.ncbi.nlm.nih.gov/pubmed/34933765 http://dx.doi.org/10.1016/j.vaccine.2021.12.006 |
work_keys_str_mv | AT goldblattdavid towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT fioregartlandandrew towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT johnsonmarina towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT huntadam towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT bengtchristopher towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT zavadskadace towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT snipehildadarta towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT brownjeremys towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT workmanlesley towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT zarheatherj towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT montefioridavid towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT shenxiaoying towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT dullpeter towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT plotkinstanley towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT sibergeorge towardsapopulationbasedthresholdofprotectionforcovid19vaccines AT ambrosinodonna towardsapopulationbasedthresholdofprotectionforcovid19vaccines |